CD47 and acute kidney injury: This catalyst hitches a ride on neutrophils to enter the AKI inflammatory environment and has demonstrated remarkably enhanced catalytic therapeutic efficacy in glycerol‐induced AKI mouse models.[22] The advantages of BCM‐NHS are as follows[23, 24, 25, 26, 27]: 1) Immune evasion and prolonged circulation: Unlike synthetic nanocarriers that often trigger immune responses, endogenous biological carriers (e.g., RBCs, platelets, leukocytes) inherently express “self‐marker” proteins (e.g., CD47) and possess surface compositions that evade phagocytic clearance.